Abstract
The objective of this study was to undertake a post- marketing safety surveillance study of losartan, the first specific angiotensin-II receptor antagonist to be marketed in England. It is a non-interventional observational cohort study using the technique of prescription-event monitoring. Subjects who took part in the study were from 14 522 patients treated by general practitioners in England. We recorded adverse drug reactions, adverse events, reasons for stopping the drug, pregnancies and deaths. The results were that general practitioners considered the drug to have been effective in 85.9% of the patients evaluated for effectiveness. Dizziness, malaise, lassitude, nausea, cough and headache were among the most frequently reported adverse drug reactions, reasons for stopping the drug and events of highest incidence density. None of the deaths that occurred were attributed to losartan and no serious unexpected adverse reactions or interactions were identified. In conclusion losartan has an acceptable safety profile and the study confirms the safety information given in the current Summary of Product characteristics for losartan.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mann, R., Mackay, F., Pearce, G. et al. Losartan: a study of pharmacovigilance data on 14 522 patients. J Hum Hypertens 13, 551–557 (1999). https://doi.org/10.1038/sj.jhh.1000880
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000880
Keywords
This article is cited by
-
Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review
Hypertension Research (2015)
-
The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England
Journal of Human Hypertension (2002)
-
Compliance and persistence with newer antihypertensive agents
Current Hypertension Reports (2002)
-
Angiotensin receptor antagonists and vaso-vagal attacks due to sensitisation of the Bezold-Jarisch reflex?
Journal of Human Hypertension (2001)